CA2250829A1 - Methode de prevention de l'infection des cellules cd4+ par le vih-1 - Google Patents

Methode de prevention de l'infection des cellules cd4+ par le vih-1 Download PDF

Info

Publication number
CA2250829A1
CA2250829A1 CA002250829A CA2250829A CA2250829A1 CA 2250829 A1 CA2250829 A1 CA 2250829A1 CA 002250829 A CA002250829 A CA 002250829A CA 2250829 A CA2250829 A CA 2250829A CA 2250829 A1 CA2250829 A1 CA 2250829A1
Authority
CA
Canada
Prior art keywords
agent
chemokine
hiv
cells
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002250829A
Other languages
English (en)
Inventor
Graham P. Allaway
Virginia M. Litwin
Paul J. Maddon
William C. Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2250829A1 publication Critical patent/CA2250829A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne une méthode permettant d'inhiber la fusion du VIH-1 et des cellules CD4?+¿ et consistant à mettre les cellules CD4?+¿ en contact avec un agent non-chémokine capable de se lier à un récepteur de chémokine dans des conditions et en quantités suffisantes pour inhiber la fusion du VIH-1 et des cellules CD4?+¿. L'invention concerne également une méthode permettant d'inhiber l'infection des cellules CD4?+¿ par le VIH-1 et consistant à mettre les cellules CD4?+¿ en contact avec un agent non-chémokine capable de se lier à un récepteur de chémokine dans des conditions et en quantités suffisantes pour inhiber la fusion du VIH-1 et des cellules CD4?+¿, ce qui permet d'inhiber l'infection par le VIH-1. De même, l'invention décrit des agents non-chémokines capables de se lier au récepteur de chémokine et d'inhiber la fusion du VIH-1 et des cellules CD4?+¿. L'invention concerne finalement des compositions pharmaceutiques comprenant une certaine quantité d'agent non-chémokine capable de se lier au récepteur de chémokine et d'inhiber la fusion du VIH-1 et des cellules CD4?+¿, ainsi qu'un excipient acceptable en pharmacologie.
CA002250829A 1996-04-02 1997-04-02 Methode de prevention de l'infection des cellules cd4+ par le vih-1 Abandoned CA2250829A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US62768496A 1996-04-02 1996-04-02
US08/627,684 1996-04-02
US66361696A 1996-06-14 1996-06-14
US08/663,616 1996-06-14
US67368296A 1996-06-25 1996-06-25
US08/673,682 1996-06-25

Publications (1)

Publication Number Publication Date
CA2250829A1 true CA2250829A1 (fr) 1997-10-09

Family

ID=27417425

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002250829A Abandoned CA2250829A1 (fr) 1996-04-02 1997-04-02 Methode de prevention de l'infection des cellules cd4+ par le vih-1

Country Status (5)

Country Link
EP (1) EP0915969A4 (fr)
JP (2) JP2000507596A (fr)
AU (1) AU728512B2 (fr)
CA (1) CA2250829A1 (fr)
WO (1) WO1997037005A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
CN1227610A (zh) * 1996-06-03 1999-09-01 美国联合生物医学公司 抗cd4和趋化因子受体结构域复合物的抗体及其抵抗hiv感染的应用
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
FR2771423A1 (fr) * 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
EP1100527A2 (fr) 1998-06-01 2001-05-23 University Of Maryland Biotechnology Institute Complexes d'antagonistes a ligand pour recepteur et leur application dans le traitement ou la prophylaxie de maladies declenchees par un recepteur
JP4824236B2 (ja) * 1999-07-09 2011-11-30 ジェン−プローブ・インコーポレーテッド 核酸増幅によるｈｉｖ−１の検出
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1723178A4 (fr) 2004-03-12 2007-12-12 Human Genome Sciences Inc Recepteur humain (ccr5) hdgnr10 de chimiokine de la proteine g
AU2006272750B2 (en) 2005-07-22 2011-09-29 Cytodyn, Inc. Methods for reducing viral load in HIV-1-infected patients
EP2053060A1 (fr) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG Antagonistes du glycosaminoglycane dérivés de SDF-1 et leurs procédés d'utilisation
CN106102781A (zh) 2013-08-29 2016-11-09 英联邦高等教育系统天普大学 用于hiv感染的rna指导的治疗的方法和组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
WO1997028258A1 (fr) * 1996-01-30 1997-08-07 The National Institutes Of Health Cellules exprimant les molecules humaines cd4 et cxcr4
ATE280826T1 (de) 1996-03-01 2004-11-15 Euroscreen Sa Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih

Also Published As

Publication number Publication date
AU2607497A (en) 1997-10-22
JP2000507596A (ja) 2000-06-20
WO1997037005A1 (fr) 1997-10-09
AU728512B2 (en) 2001-01-11
JP2008069148A (ja) 2008-03-27
EP0915969A4 (fr) 2002-04-17
EP0915969A1 (fr) 1999-05-19

Similar Documents

Publication Publication Date Title
US6344545B1 (en) Method for preventing HIV-1 infection of CD4+ cells
AU753362B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU728512B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU735460B2 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
Dragic et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5
Willett et al. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses
US20060194244A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
US6214540B1 (en) Chemokines that inhibit immunodeficiency virus infection and methods based thereon
Burns et al. A new monoclonal antibody, mAb 4A12, identifies a role for the glycosaminoglycan (GAG) binding domain of RANTES in the antiviral effect against HIV-1 and intracellular Ca2+ signaling
US7935797B2 (en) CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion
AU776239B2 (en) Method for preventing HIV-1 infection of CD4+ cells
AU2004233505B2 (en) Method for preventing HIV-1 infection of CD4+ cells
Cormier et al. An overview of HIV-1 coreceptor function and its inhibitors
JP4116087B2 (ja) 新規マウスｃｘｃケモカインレセプター
AU2004205143A1 (en) Uses of a chemokine receptor for inhibiting HIV-1 infection
MXPA98010425A (en) Uses of a chemiocine receiver to inhibit theinfection with human immunodeficiency viruses
EP1015485A1 (fr) Chemokine derivee d'un macrophage (mdc) en tant qu'agent antiviral pour traiter et prevenir des infections par lentivirus
Combadiere et al. Identification of CX3CR1
Choi Biochemical characterization of CXCR4 interactions with HIV-1, natural ligands and de novo designed inhibitors
Burns Structural and functional analysis of the β-chemokine RANTES: Proposal of a three-site binding hypothesis

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued